Phase II Study of Diclofenac Salvage in Patients Metastatic Non-Small Cell Lung Cancer With Early Signs of Progression on Single Agent PD(L)-1 Blockade
Latest Information Update: 17 Feb 2026
At a glance
- Drugs Cemiplimab (Primary) ; Diclofenac (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 12 Feb 2026 Planned End Date changed from 1 Jan 2027 to 1 Jan 2028.
- 12 Feb 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2027.
- 12 Jun 2025 Status changed from not yet recruiting to recruiting.